Literature DB >> 20963627

Links between cyclosporin exposure in tissues and graft-versus-host disease in pediatric bone marrow transplantation: analysis by a PBPK model.

Cécile Gérard1, Nathalie Bleyzac, Pascal Girard, Gilles Freyer, Yves Bertrand, Michel Tod.   

Abstract

PURPOSE: In hematopoietic stem cell transplantation (HSCT), cyclosporin is used to prevent graft-versus-host disease (GVHD). However, cyclosporin distribution in tissues is not linear, resulting in uncertainty regarding optimal dosing and monitoring. The objective of this study was to link the probability and severity of acute GVHD to cyclosporin exposure in blood, GVHD target organs, and lymphoid organs.
METHODS: A physiologically based pharmacokinetic model of cyclosporin disposition and logistic regression models were used. Sixty-one pediatric patients undergoing HSCT were studied. Cyclosporin was administered by intermittent (n = 31) or continuous infusion (n = 30).
RESULTS: At steady state (1 day before acute GVHD), exposures in all organs were related with the probability and severity of acute GVHD. Average cyclosporin concentration or, equivalently, its area under the curve (AUC) was the pharmacokinetic index best correlated with the anti-GVHD effect. Cyclosporin AUC in interstitial fluid of lymphoid organs was a superior index than that in blood, but marginally.
CONCLUSION: Hence, AUC in blood maybe used as an index of cyclosporin efficacy. Using our model, target AUCs in blood could be defined for malignant and non-malignant diseases, as well as the equivalent target values for C(2) and C(0) concentrations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20963627     DOI: 10.1007/s11095-010-0299-z

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  28 in total

1.  C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients.

Authors:  Alida L P Caforio; Francesco Tona; Stefano Piaserico; Antonio Gambino; Giuseppe Feltrin; Anna Belloni Fortina; Annalisa Angelini; Mauro Alaibac; Martina Bontorin; Diego Calzolari; Andrea Peserico; Gaetano Thiene; Sabino Iliceto; Gino Gerosa
Journal:  Transpl Int       Date:  2005-01       Impact factor: 3.782

2.  Target range maximum of cyclosporine blood concentration two hours post dose in stable liver transplant patients.

Authors:  J Li; Uta Dahmen; S Beckebaum; V Cicinnati; C Valentin-Gamazo; A Frilling; M Malago; C E Broelsch
Journal:  Eur J Med Res       Date:  2006-04-28       Impact factor: 2.175

3.  A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT.

Authors:  T Ruutu; D Niederwieser; A Gratwohl; J F Apperley
Journal:  Bone Marrow Transplant       Date:  1997-04       Impact factor: 5.483

4.  Influence of dosing schedule on organ exposure to cyclosporin in pediatric hematopoietic stem cell transplantation: analysis with a PBPK model.

Authors:  Cécile Gérard; Nathalie Bleyzac; Pascal Girard; Gilles Freyer; Yves Bertrand; Michel Tod
Journal:  Pharm Res       Date:  2010-09-02       Impact factor: 4.200

5.  Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.

Authors:  H Glucksberg; R Storb; A Fefer; C D Buckner; P E Neiman; R A Clift; K G Lerner; E D Thomas
Journal:  Transplantation       Date:  1974-10       Impact factor: 4.939

6.  Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients.

Authors:  M P Hendriks; N M A Blijlevens; A V M B Schattenberg; D M Burger; J P Donnelly
Journal:  Bone Marrow Transplant       Date:  2006-10       Impact factor: 5.483

7.  Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.

Authors:  L Barkholt; M Remberger; H Bodegård; O Ringdén; Y Böttiger
Journal:  Bone Marrow Transplant       Date:  2007-07-30       Impact factor: 5.483

8.  Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion.

Authors:  N Ogawa; Y Kanda; M Matsubara; Y Asano; M Nakagawa; M Sakata-Yanagimoto; K Kandabashi; K Izutsu; Y Imai; A Hangaishi; M Kurokawa; S Tsujino; S Ogawa; K Aoki; S Chiba; T Motokura; H Hirai
Journal:  Bone Marrow Transplant       Date:  2004-03       Impact factor: 5.483

9.  Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.

Authors:  P Troncoso; A M Ortiz; A Jara; S Vilches
Journal:  Transplant Proc       Date:  2009 Jan-Feb       Impact factor: 1.066

10.  Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors.

Authors:  P Martin; N Bleyzac; G Souillet; C Galambrun; Y Bertrand; P H Maire; R W Jelliffe; G Aulagner
Journal:  Bone Marrow Transplant       Date:  2003-10       Impact factor: 5.483

View more
  6 in total

Review 1.  Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.

Authors:  Jennifer E Sager; Jingjing Yu; Isabelle Ragueneau-Majlessi; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2015-08-21       Impact factor: 3.922

Review 2.  Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.

Authors:  Jeannine S McCune; Meagan J Bemer; Janel Long-Boyle
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

3.  Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis.

Authors:  N Bleyzac; D Cuzzubbo; C Rénard; N Garnier; V Dubois; C Domenech; M-P Goutagny; A Plesa; N Grardel; S Goutelle; A Janoly-Duménil; Y Bertrand
Journal:  Bone Marrow Transplant       Date:  2016-01-25       Impact factor: 5.483

Review 4.  Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I.

Authors:  Jeannine S McCune; Meagan J Bemer
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

5.  Bayesian approach for the estimation of cyclosporine area under the curve using limited sampling strategies in pediatric hematopoietic stem cell transplantation.

Authors:  Sarem Sarem; Jun Li; Olivier Barriere; Catherine Litalien; Yves Théorêt; Anne-Laure Lapeyraque; Fahima Nekka
Journal:  Theor Biol Med Model       Date:  2014-09-05       Impact factor: 2.432

6.  Initial dosage optimization of ciclosporin in pediatric Chinese patients who underwent bone marrow transplants based on population pharmacokinetics.

Authors:  Xiao Chen; Xin Yu; Dong-Dong Wang; Hong Xu; Zhiping Li
Journal:  Exp Ther Med       Date:  2020-05-08       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.